Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™ its Low-energy Radiation Therapy Systems for Treating Skin Cancer - The products have demonstrated safety, clinical efficacy, and potential for widespread adoption to treat a host of dermatological and oncological conditions
Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™ its Low-energy Radiation Therapy Systems for Treating Skin Cancer

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2014/03/20 - The products have demonstrated safety, clinical efficacy, and potential for widespread adoption to treat a host of dermatological and oncological conditions.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two low-energy X-ray devices, SRT-100™ and SRT-100 Vision™. Low energy X-rays are often used for medical imaging and for the treatment of certain cancers. The SRT-100™ and SRT-100 Vision™ devices are superior to other available treatments of non-melanoma skin cancer and other skin conditions. They offer unrivaled value to patients and physicians through safe, effective, and virtually pain- and scar-free treatment options.

Competing products use electron beams ranging from 1 to 12 mega electron volts (MeV), or decaying isotope-based emitting sources. They are also bulky, complex and expensive to operate and maintain. Furthermore, the patients are subjected to radiation levels many times the energy required for non-melanoma skin cancer treatment, with only a part of the energy being delivered to the surface of the skin.

In contrast, Sensus Healthcare’s SRT-100™ and SRT-100 Vision™ use kilovoltage X-rays in the 50 to 100 kilo volts (KV) energy range. The radiation is delivered completely to the surface of the skin, without affecting the underlying healthy tissue and cells. SRT is ideal for irradiating tumorous growths at depths of between 0.5 mm and 5 mm.

SRT-100™ and SRT-100 Vision™ are small footprint and portable devices, similar in size and design to an ultrasound instrument. Interestingly, Sensus’ next-generation SRT device, the SRT-100 Vision™, integrates high-resolution ultrasound imaging and laser positioning capabilities to help with the accurate localization, characterization, and topology of lesions. This, in turn, will ensure optimal energy dosage, treatment fractionation and depth of beam penetration.

"SRT-100™ and SRT-100 Vision™ utilize a non-invasive approach that does not leave scars and therefore, eliminates the need for additional follow-up procedures, such as skin grafting and cosmetic reconstructive surgeries," said Frost & Sullivan Research Analyst Bhargav Rajan. "There is no loss of skin and/or sensation, and since it is a non-contact procedure, it is painless. The entire procedure lasts only seconds for each treatment fraction, compared to surgeries and other procedures, which take hours and additional recovery time."

A retrospective assessment of over 1,700 patients who were treated for basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) using SRT-100™ showed a 98 percent cure rate over two years, and over 95 percent cure rate over five years. These remarkable cure rates are comparable with those obtained using current clinical standards.

"SRT-100™ has come to be considered medically necessary and/or an adjunctive procedure for the treatment of non-melanoma skin cancers and non-oncological skin conditions such as keloids," noted Rajan. "Due to its record for safety, efficacy, and low risks, it is covered by most insurance companies and Medicare for oncological and non-oncological procedures."

SRT-100™’s penetration potential got a boost with the United States Food and Drug Administration (FDA) 510(K) recently clearing it to treat keloids, which are collagen-based non-malignant scars. With this regulatory approval, SRT-100™ and SRT-100 Vision™ can now be used to treat non-oncological conditions (keloids) and pre-oncological conditions such as actinic keratosis. For all of these applications, the SRT-100™ and SRT-100 Vision™ have FDA 510(K) clearance, the European Union’s CE mark, and the ISO quality certification. The company is actively looking at expanding its geographic presence beyond the US, Europe, Australia, Africa, and Canada into additional regions in Europe, Asia, and Latin America.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value added features/benefits of the product and the increased ROI it offers customers, which in turn increases customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Sensus Healthcare, LLC
Sensus Healthcare LLC (Boca Raton, FL) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities.

Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™ its Low-energy Radiation Therapy Systems for Treating Skin Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan | Sensus Healthcare, LLC
Contact: Mireya Espinoza - Frost.com 
210-247-3870 mireya.espinoza[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com

Visit  JobsWare.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today